Phase 2b study

Related by string. Phase 2b Study * phase . phases . Phases . PHASE . PHASES : Phase III clinical trials . Phase III trials . Phase III clinical . pivotal Phase III . ongoing Phase 1b / 2Bs . 2BD . 2B : 2B Marcus Giles . Phase 2b clinical . 2B Luis Castillo . 2b SAC bunt . 2B Freddy Sanchez / studying . Studying . STUDY . studys . STUDYING : Pre Feasibility Study . Case Study . Study Shows . Study Reveals * *

Related by context. All words. (Click for frequent words.) 82 Phase IIb 81 Phase 2a trial 81 Phase 2b trial 80 Phase 2a 80 Phase IIa trial 80 Phase 2a clinical 80 Phase IIb trial 80 Phase 2b clinical 79 phase IIb clinical 79 Phase Ib 79 Phase 1b 79 Phase IIa 78 phase IIa clinical 78 Phase III clinical 78 phase IIb 78 Phase Ib clinical 78 phase IIa 78 Phase IIb clinical 77 Phase 2b 77 Phase IIa clinical 77 pivotal Phase III 76 Phase 1b clinical 76 Phase III 76 dose escalation trial 75 Phase 1b trial 75 Phase IIb trials 75 Phase Ib study 75 phase 2a 74 Phase 1a 74 Phase III trials 74 phase IIb trial 74 phase IIb study 74 Phase Ia 73 clinical trial 73 multicenter Phase 73 phase Ib 73 Phase #/#a 73 Phase 2b clinical trials 72 Phase Ib II 72 Phase III clinical trials 72 placebo controlled Phase 72 pivotal Phase 72 Phase #b/#a 72 Phase III pivotal 72 Phase IIIb clinical 72 dose escalation Phase 72 Phase IIIb 71 Phase IIB 71 SUCCEED trial 71 multiple ascending dose 71 multicenter Phase II 71 confirmatory Phase III 71 Phase Ib clinical trials 71 IIa trial 71 randomized Phase 71 dirucotide 71 dose escalation study 70 placebo controlled clinical 70 Phase IIb clinical trials 70 dose escalation 70 BRIM2 70 randomized controlled Phase 70 Phase 1a clinical 70 oral ridaforolimus 70 GALNS 70 multicenter clinical 70 Phase II 69 elotuzumab 69 dose escalation clinical 69 Phase IIa trials 69 pharmacokinetic PK 69 randomized Phase IIb 69 registrational trial 69 NO# [002] 69 registrational 69 PRX # 69 ENDEAVOR IV 68 multicenter randomized placebo controlled 68 dose cohorts 68 BRIM3 68 pharmacokinetic PK study 68 confirmatory Phase 3 68 MEND CABG 68 forodesine 68 single ascending dose 68 double blinded placebo 68 Phase 2a clinical trials 68 HCV SPRINT 68 phase Ib clinical 68 placebo controlled 68 GLP toxicology studies 68 PSN# [002] 68 elagolix 68 viral kinetic 68 JAK inhibitor 68 clinical trials 68 randomized placebo controlled 68 Phase IIa clinical trials 68 ADVANCE PD 68 INCB# [001] 68 Dacogen injection 68 Traficet EN 68 placebo controlled Phase III 68 CR# vcMMAE 68 bicifadine 68 IND submission 68 RSD# oral 67 randomized Phase III 67 TMC# C# 67 ozarelix 67 randomized multicenter 67 PRT# 67 IIa clinical trial 67 ongoing Phase 1b 67 dose cohort 67 pharmacokinetic studies 67 Phase 2b randomized 67 multicentre randomized 67 alvespimycin 67 Pivotal Trial 67 randomized Phase 2b 67 phase IIIb 67 HCV RESPOND 2 67 glufosfamide 67 RG# [001] 67 double blind placebo 67 cannabinor 67 PEG PAL 67 clinical pharmacology studies 67 Phase III randomized controlled 67 rALLy clinical trial 67 Phase III Clinical Trial 67 Phase 1b dose escalation 67 pivotal bioequivalence 67 Amrubicin 67 dosing cohorts 66 randomized controlled 66 APEX PD 66 budesonide foam 66 nab paclitaxel 66 multicenter randomized double 66 NP2 Enkephalin 66 PFO migraine 66 tolerability 66 Fx #A 66 CUSTOM III 66 Mipomersen 66 NGX# 66 ABSORB trial 66 multicenter phase 66 axitinib 66 Phase #b/#a trial 66 controlled multicenter 66 cetrorelix 66 teduglutide 66 IMGN# 66 GAMMAGARD 66 Augment Injectable 66 Corlux 66 FOLOTYN ® 66 KRN# 66 Plicera 66 oral prodrug 66 deforolimus 66 rALLy trial 66 placebo controlled randomized 66 Bicifadine 66 active comparator 66 investigational compound 66 multicenter 66 octreotide implant 66 darusentan 66 multicenter randomized Phase 66 HuMax CD4 66 TBC# 66 APPRAISE 65 lomitapide 65 pertuzumab 65 denufosol 65 prospective multicenter 65 HspE7 65 EVIZON 65 elacytarabine 65 blind randomized placebo 65 OncoVEX GM CSF 65 RSD# 65 PREOS 65 ACTEMRA TM 65 phase III ACCLAIM 65 Phase IIIb study 65 unblinded 65 initiate Phase IIb 65 Cloretazine ® 65 HGS ETR1 65 ELACYT 65 Cloretazine R VNP#M 65 DSMB 65 relapsed refractory multiple myeloma 65 masked placebo controlled 65 IND enabling 65 label multicenter 65 BAY #-# 65 pharmacokinetics PK 65 APTIVUS 65 unblinding 65 ADAGIO study 65 multicenter Phase III 65 confirmatory clinical 65 diabetic neuropathic pain 65 Phase III Pivotal 65 MERLIN TIMI 65 relapsed multiple myeloma 65 randomized double 65 alvimopan 65 initiate Phase 2b 65 lorvotuzumab mertansine 65 Phase III randomized 65 opioid induced bowel dysfunction 65 brivaracetam 65 AEGR 65 rNAPc2 65 cangrelor 65 EOquin 65 randomized controlled clinical 65 oral deforolimus 65 Zenvia Phase III 65 CLIRS trial 65 phase IIb III 64 riociguat 64 CRMD# 64 subcutaneously administered 64 SPIRIT FIRST 64 AIR CF1 64 double blinded randomized 64 evaluating tivozanib 64 randomized multicenter trial 64 eltrombopag 64 CCR5 antagonist 64 multicenter randomized 64 blinded randomized placebo controlled 64 ANCHOR trial 64 PS# [001] 64 dosing cohort 64 II Clinical Trial 64 Phase III placebo controlled 64 selective androgen receptor modulator 64 European Sepsis Trial 64 Elagolix 64 SYMMETRY trial 64 randomized clinical 64 Ozarelix 64 safety tolerability pharmacokinetics 64 administered subcutaneously 64 efficacy endpoint 64 AQ4N 64 Phase III confirmatory 64 AZILECT R 64 celgosivir 64 MBP# [001] 64 ganetespib 64 Pivotal Phase 64 nitazoxanide 64 Phase #b/#a clinical 64 PRECiSE 64 Aurexis 64 teriflunomide 64 multicenter study 64 R#/MEM # 64 nonrandomized 64 CRx 64 ZYBRESTAT 64 mipomersen 64 Androxal TM 64 eprotirome 64 enzastaurin 64 ocrelizumab 64 Nasulin 64 midstage trials 64 MEND CABG II 64 Pimavanserin 64 prospective randomized controlled 64 Phase IIb III 64 HGS# 64 tremelimumab 64 Alzhemed TM 64 PRIMO CABG 64 PANVAC VF 64 PHX# 64 fosbretabulin 64 prospective randomized 64 oral formulation 64 Archexin 64 pharmacodynamic effects 64 nonclinical studies 64 tanespimycin 64 Board DSMB 64 ENDEAVOR III 64 Phenoptin 64 PRE SURGE 64 multicenter placebo controlled 64 huN# DM1 64 Proxinium TM 64 ularitide 64 albinterferon alfa 2b 64 blinded placebo controlled 64 ENDEAVOR II 64 pharmacokinetic 64 PF # [001] 64 Pivotal Phase III 64 INCB# [002] 64 tesmilifene 63 OPT CHF 63 Ostarine 63 NVA# 63 preclinical 63 eptifibatide 63 Amigal 63 pradefovir 63 CHAMPION PCI 63 Viramidine 63 TACI Ig 63 Randomized Phase 63 Laquinimod 63 GetGoal Phase III 63 AEG# 63 initiate Phase 1b 63 trastuzumab DM1 T DM1 63 HuMax EGFr 63 Ophena TM 63 randomized blinded 63 CoFactor 63 Phase IIb Trial 63 oral methylnaltrexone 63 SCH # 63 CIMZIA TM 63 EOquin TM 63 SinuNase 63 Fibrillex TM 63 Phase #/#a trial 63 PXD# 63 dexanabinol 63 ISIS # 63 investigational humanized monoclonal antibody 63 CRLX# 63 Initiate Phase 63 Myocet 63 lesinurad 63 olaparib 63 Microplasmin 63 REVLIMID lenalidomide 63 midstage studies 63 Adlea 63 reslizumab 63 Panzem R NCD 63 omacetaxine mepesuccinate 63 DAPT 63 IMA# 63 ADX# 63 HuMax CD# 63 Xanafide 63 metastatic hormone refractory 63 mertansine 63 metastatic HRPC 63 pomalidomide 63 virus HCV protease inhibitor 63 COMFORT II 63 QLT# 63 IPL# 63 generation purine nucleoside 63 huC# DM4 63 Bezielle 63 LE SN# 63 Phase III Clinical Trials 63 ofatumumab 63 AeroLEF TM 63 ascending doses 63 preclinical efficacy 63 IIa clinical 63 AIR CF2 63 TEMSO 63 AzaSite Plus 63 FOLOTYN 63 dose dose escalation 63 velafermin 63 ATL# [001] 63 prucalopride 63 ascending dose 63 valopicitabine 63 RE LY ® 63 multicentre randomized double 63 PDX pralatrexate 63 BLA filing 63 Phase III VISTA 63 Dextofisopam 63 placebo controlled studies 63 edoxaban 63 Alocrest 63 PDE4 inhibitor 63 LUX Lung 63 BCX# 63 assessing T DM1 63 dalbavancin 63 CB2 selective receptor agonist 63 Asentar 63 pharmacodynamic profile 63 incyclinide 63 PROMACTA 63 ponatinib 63 eculizumab 63 OHR/AVR# 63 ALN TTR# 63 subcutaneous formulation 63 Itopride 63 LibiGel Phase III 63 sNDA submission 63 ribavirin RBV 63 obatoclax 63 dyskinesia PD LID 63 GEM OS2 63 aflibercept 63 histone deacetylase HDAC inhibitor 63 PEARL SC 63 Omigard 63 AVADO 63 PRTX 63 EchoCRT 63 CIMZIA ™ 63 mg/m2 cohort 63 visilizumab 63 EFAPROXYN 63 TAXUS ATLAS 63 fostamatinib 63 prospective multicenter randomized 63 Matrix Phase 2b 62 peginesatide 62 belinostat 62 metastatic sarcomas 62 mGluR5 negative 62 MIRCERA 62 severe hypercholesterolemia 62 Gabapentin GR 62 Quinamed 62 secondary efficacy endpoints 62 NLX P# 62 NEVO ™ 62 Phase III Trial 62 Locteron ® 62 Phase III psoriasis 62 unblind 62 inhaled formulation 62 initiate Phase 62 oral rivaroxaban 62 Apoptone 62 vidofludimus 62 Maximum Tolerated Dose 62 ILUVIEN ® 62 refractory CLL 62 AZILECT ® 62 treatment naive genotype 62 ENRICH trial 62 Azedra 62 INT# [002] 62 Zybrestat 62 tolerated dose MTD 62 VNP#M 62 AZX# 62 multicentre 62 IRX 2 62 DASISION 62 NUVIGIL 62 EDEMA3 62 PROPEL trial 62 VITAL Trial 62 Zenvia ™ 62 Q#IR 62 arzoxifene 62 vicriviroc 62 cell lymphoma CTCL 62 EndoTAG TM -1 62 Cannabinor 62 investigational pan BCR 62 ruxolitinib 62 docetaxel chemotherapy 62 DR Cysteamine 62 Phase 2b Clinical Trial 62 Sorafenib HCC Assessment 62 TELINTRA 62 Carfilzomib 62 bardoxolone 62 PRECISE Trial 62 neratinib 62 Phase III HEAT 62 microplasmin 62 TLK# 62 tezampanel 62 Onalta ™ 62 crizotinib PF # 62 LEVADEX 62 cancer neuroendocrine tumor 62 Urocidin 62 lintuzumab 62 pharmacodynamics PD 62 PROVENGE sipuleucel T 62 ARDIS 62 anticancer compound 62 trastuzumab emtansine T DM1 62 Anturol TM 62 Pivotal Study 62 DB# [003] 62 ROCKET AF 62 Phase III ALLEGRO 62 Capesaris 62 ritonavir boosted 62 GSK# [002] 62 custirsen 62 Zerenex 62 TELCYTA 62 NEBIDO 62 monotherapy 62 XL# [003] 62 Elocalcitol 62 Aflibercept 62 Phase 1b clinical trials 62 GOUT 62 LibiGel ® 62 pharmacodynamic PD 62 prospective randomized multicenter 62 ZYBRESTAT fosbretabulin 62 Troxatyl 62 label dose escalation 62 blinded randomized 62 tolevamer 62 IIb clinical trial 62 MGCD# [001] 62 IMPACT IMmunotherapy 62 prospective observational 62 TRANSFORMS 62 Ceflatonin R 62 TMC# [002] 62 Personalized Immunotherapy 62 adecatumumab 62 superficial bladder cancer 62 ProSavin 62 picoplatin 62 carboplatin paclitaxel 62 MIST II 62 treatment naïve genotype 62 bendamustine 62 PRIMO CABG2 62 mapatumumab 62 baminercept 62 acyclovir Lauriad R 62 metastatic renal cell carcinoma 62 preclinical studies 62 GEM OS1 62 Chemophase 62 mTOR inhibitor 62 Rezular 62 Dose escalation 62 Phase Ib IIa 62 receptor tyrosine kinase inhibitor 62 GED aPC 62 otelixizumab 62 OvaRex ® MAb 62 Urocortin 2 62 CA4P 62 QNEXA 62 mg QD 62 Phase IIb kidney transplant 62 Investigational Device Exemption IDE 62 PEG Interferon lambda 62 mg dose 62 Factor VIIa 62 CCX# 62 ITAX 62 cariprazine 62 randomized multicenter Phase III 62 NDA submission 62 PEG SN# 62 BLA submission 62 VA# [002] 62 NOX E# 62 BrachySil TM 62 Azixa 62 eniluracil 62 torezolid phosphate 62 Phase IIb Clinical Trial 62 IMC A# 62 hormone refractory prostate cancer 62 Phase 2b kidney transplant 62 CLARITY study 61 injectable formulation 61 inhibitor RG# 61 PD LID 61 Cimzia TM 61 APEX AMI trial 61 CCX# B 61 Exherin TM 61 Triolex 61 ulimorelin 61 tivozanib 61 PREOS R 61 confirmatory Phase 61 Ocrelizumab 61 AP# [003] 61 fidaxomicin Phase 3 61 neurogenic orthostatic hypotension 61 OvaRex R 61 Cloretazine 61 ILLUMINATE 61 dexpramipexole 61 pegloticase 61 DDP# 61 Zoraxel 61 HER2 positive metastatic breast 61 ORENCIA ® 61 MAA submission 61 prospectively defined 61 MAXY alpha 61 miconazole Lauriad ® 61 antibody MAb 61 MAGE A3 ASCI 61 sunitinib malate 61 GRAVITAS trial 61 investigational drug 61 recurrent GBM 61 dose escalation phase 61 dimebon 61 randomized 61 carfilzomib 61 investigational antiplatelet agent 61 Menerba 61 urocortin 2 61 ToGA 61 multicenter randomized controlled 61 polymerase inhibitor 61 Targretin 61 Phase III metastatic melanoma 61 oxymorphone ER 61 IDX# 61 ARIKACE 61 Darusentan 61 Allovectin 7 61 vosaroxin 61 Triapine 61 ASA# 61 prospective randomized placebo 61 refractory gout 61 Stedivaze 61 RhuDex ® 61 safety tolerability 61 rALLy 61 glatiramer acetate 61 romidepsin 61 trastuzumab DM1 61 sunitinib 61 multicenter prospective 61 Prostate AdenoCarcinoma Treatment 61 lumiliximab 61 trials RCTs 61 YONDELIS 61 dose titration 61 palifosfamide 61 relapsing remitting multiple sclerosis 61 ospemifene 61 nalbuphine ER 61 Hyphanox 61 AGILECT R 61 albiglutide 61 ocular formulation 61 REVIVE Diabetes 61 NATRECOR ® 61 IL# PE#QQR 61 catheter occlusion 61 desvenlafaxine succinate 61 GLPG# 61 APTIVUS r 61 IMPACT DCM 61 EmbraceAC 61 HRPC 61 Catena ® 61 tolerability profile 61 viral kinetics 61 LEUKINE 61 pralatrexate injection 61 SinuNase TM 61 goserelin 61 investigational oral 61 interferon beta 1b 61 diarrhea predominant irritable 61 tecarfarin 61 LCP Tacro 61 Testosterone MDTS ® 61 dosing regimens 61 JZP 61 Aryplase 61 TG MV 61 Initiated Phase 61 ThermoDox R 61 CEQ# 61 VQD 61 CTAP# Capsules 61 ofatumumab HuMax CD# 61 Acute Ischemic Stroke 61 SEPET TM 61 LymphoStat B 61 non nucleoside inhibitor 61 nucleotide analog 61 COU AA 61 ATACAND 61 relapsing multiple sclerosis 61 EDEMA4 61 bardoxolone methyl 61 lintuzumab SGN 61 omega interferon 61 Ereska 61 BCIRG 61 maximally tolerated dose 61 mixed dyslipidemia 61 metaglidasen 61 generation NNRTI 61 Veronate 61 Gattex 61 null responder HCV 61 AIR CF3 61 dasatinib Sprycel ® 61 Viprinex 61 Spiegelmer ® 61 CLIRS 61 pharmacokinetic profile 61 XL# SAR# 61 Tyrima 61 PEG IFN 61 docetaxel Taxotere R 61 Parkinson disease levodopa induced 61 Diabetic Macular Edema DME 61 BR.# 61 NATRECOR R 61 placebo controlled clinical trials 61 IMPACT DCM clinical 61 PEGINTRON TM 61 EVEREST II 61 alfimeprase 61 symptomatic BPH 61 sapacitabine 61 CBLC# 61 davunetide intranasal AL 61 Ixempra 61 SPIRIT IV 61 Annamycin 61 subgroup analyzes 61 severe gastroparesis 61 trial evaluating PRX# 61 Desmoteplase 61 Sym# 61 evaluating RDEA# 61 MAP# 61 dirucotide MBP# 61 eosinophilic asthma 61 Serdaxin 61 Inhalation Solution 61 Pharmacokinetics PK 61 Relovair 61 BOLDER II 61 PMA submission 61 immunomodulatory therapy 61 Feasibility Trial 61 PS# DARA 61 T Pred 61 R# #mg BID 61 PA# [002] 61 Cethromycin 60 XmAb# 60 blinatumomab 60 Iluvien ® 60 Aurora kinase inhibitor 60 PSMA ADC 60 ZOLINZA 60 Locteron 60 TOCOSOL Paclitaxel 60 Nasdaq PGNX today 60 MEK inhibitor RDEA# 60 RezularTM 60 Safinamide 60 novel histone deacetylase 60 RSD# iv 60 talactoferrin 60 orally bioavailable 60 blind randomized 60 PRECISE trial 60 HZT 60 AGGRASTAT R 60 LCP AtorFen 60 Proellex TM 60 Clolar ® 60 evaluating REVLIMID 60 EXPAREL TM 60 budesonide MMX 60 liposomal formulation 60 investigational protease inhibitor 60 PNP inhibitor 60 Phase 2b monotherapy 60 MoxDuo IR 60 Prosaptide 60 ALTU 60 midstage clinical 60 motesanib 60 CYCLOSET 60 telaprevir dosing 60 ThermoDox ® 60 safety tolerability pharmacokinetic 60 zanolimumab 60 Tamibarotene 60 posaconazole 60 mRCC 60 acute PAO 60 pharmacodynamics 60 RGB # 60 SAR# [004] 60 blind placebo controlled 60 castration resistant prostate cancer 60 evaluable patients 60 ocular hypertension 60 entinostat 60 non inferiority 60 SABCS 60 MYDICAR 60 Efficacy Results 60 refractory AML 60 metastatic castration resistant 60 Diabetic Macular Edema 60 Dapagliflozin 60 Plenaxis TM 60 methylnaltrexone 60 resminostat 60 MOZOBIL 60 DU #b 60 bosutinib 60 atrasentan 60 Degarelix 60 rFIXFc 60 bevirimat Study 60 #mg QD [002] 60 apremilast 60 trodusquemine 60 dextofisopam 60 ACAPODENE 60 carcinogenicity study 60 Memryte 60 REG1 60 TPI ASM8 60 MIVI III 60 LB# [003] 60 Lixivaptan 60 sitaxsentan 60 Ceflatonin 60 CLORETAZINE TM VNP#M 60 efficacy 60 Nuvion 60 vascular disrupting agent 60 DSMB recommended 60 Hsp# inhibitor 60 REG2 60 BEMA TM Fentanyl 60 lubiprostone 60 Zenvia TM 60 Ventavis 60 EDEMA3 trial 60 cediranib 60 Fodosine 60 pharmacokinetics 60 MGd 60 azilsartan medoxomil 60 ORMD 60 zalutumumab 60 thymalfasin 60 HCV protease inhibitor 60 Pegasys plus Copegus 60 RE SURGE 60 SPIRIT III 60 ruboxistaurin 60 TH# [003] 60 Medidur TM FA 60 PRX# 60 rapid virologic response 60 HCD# [002] 60 NEO3 60 LEP ETU 60 Shigamabs ® 60 HCV NS5B polymerase 60 Clonicel 60 tezampanel NGX# 60 GVAX 60 HeFT 60 heavily pretreated 60 orBec 60 analgesic efficacy 60 TORISEL 60 M6G 60 terlipressin 60 Allovectin 7 ® 60 lixisenatide 60 Allovectin 7 R 60 Marqibo 60 Vilazodone 60 rindopepimut 60 Viprinex TM 60 TRO# 60 betrixaban 60 Trofex 60 telaprevir VX 60 DXL# 60 Randomized Evaluation 60 castrate resistant prostate cancer 60 dextromethorphan quinidine 60 CANCIDAS 60 standard chemotherapy regimen 60 CytoFabTM 60 TG# [003] 60 L BLP# 60 iclaprim 60 XL# XL# XL# 60 satraplatin Phase 60 vandetanib 60 HGS ETR2 60 preclinical toxicology 60 ICA # 60 LIALDA 60 randomized discontinuation trial 60 tiapamil 60 tolvaptan 60 Kamada AAT 60 tasimelteon 60 CONSERV 60 varespladib 60 OMAPRO 60 Phase 60 Genz # 60 subcutaneous SC 60 lead Aganocide compound 60 ONTAK 60 amrubicin 60 sorafenib Nexavar 60 MDV# 60 RE LY 60 refractory metastatic colorectal cancer 60 EMPHASIS HF trial 60 AIMM trial 60 Sulonex 60 PF # [002] 60 STRIDE PD 60 randomized controlled multicenter 60 Meets Primary Endpoint 60 plus ribavirin 60 Phase lll 60 interferon gamma 1b 60 MabCampath 60 NSABP 60 recurrent glioblastoma multiforme 60 Alfimeprase 60 OMNARIS HFA 60 Tarceva TM 60 TASKi2 60 pazopanib 60 MEK inhibitor 60 CALGB # [002] 60 PREGNANT Study 60 AVERROES 60 Chrysalin 60 AAG geldanamycin analog 60 candesartan cilexetil 60 transcriptase inhibitor NNRTI 60 randomized #:# 60 chemoradiotherapy 60 cystinosis patients 60 muraglitazar 60 plasma kallikrein inhibitor 60 ELND# 60 GFT# 60 Pivotal Clinical Trial 60 dacetuzumab 60 oxypurinol 60 Omnitarg 60 Reverset 60 Candesartan 60 Aclidinium 60 Hsp# Inhibitor 60 BAL# [002] 60 CIMZIA TM certolizumab pegol 60 MKC# MKC# PP 59 TKB# 59 pralatrexate 59 iniparib 59 Vicinium TM 59 PROMUS Element Stent 59 labial herpes 59 Clinical Trial Results 59 PEGylated interferon beta 1a 59 lexidronam injection

Back to home page